Blood Sample Analysis for Multiple Myeloma

Recruiting at 1 trial location

Overseen By Irene Ghobrial, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Dana-Farber Cancer Institute

Disqualifiers: Cancer requiring therapy, Plasma cell dyscrasia

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

30000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand how early conditions, such as MGUS and smoldering multiple myeloma (both early forms of blood disorders), progress to multiple myeloma, a type of blood cancer. By studying blood samples, researchers hope to identify risk factors that predict this progression. The trial is suitable for individuals over 30 who are African American or have close family members with specific blood cancers. Participants should not have any active cancers requiring treatment. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could lead to early detection and prevention strategies.

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Why are researchers excited about this trial?

Researchers are excited about the PROMISE trial because it aims to detect multiple myeloma precursor conditions early by analyzing blood samples. Unlike current methods, which often rely on symptoms or more invasive procedures, this approach focuses on early detection in high-risk individuals through a simple blood test. The hope is that by identifying these precursor conditions sooner, doctors can monitor and potentially intervene before myeloma fully develops, offering a proactive strategy against this type of cancer.

Who Is on the Research Team?

Irene Ghobrial, MD

Principal Investigator

Dana-Farber Cancer Institute

Are You a Good Fit for This Trial?

Inclusion Criteria

Age ≥ 30 years

AA race (self-identified) and/or first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Specimen Collection

Samples of blood are collected and analyzed to test for multiple myeloma precursor conditions

1-2 weeks

1 visit (in-person)

Follow-up

Participants are monitored for progression to symptomatic multiple myeloma

15 years

What Are the Treatments Tested in This Trial?

Interventions

• Sample of Blood

How Is the Trial Designed?

Group I: Specimen Collection Experimental Treatment 1 Intervention

* Samples of blood (2-4 tablespoons) from 4 tubes will be collected * Analysis will be performed on the blood to test for multiple myeloma precursor conditions.

Who Is Running the Clinical Trial?

Dana-Farber Cancer Institute

Lead Sponsor

Trials

1,128

Recruited

382,000+

Stand Up To Cancer

Collaborator

Trials

53

Recruited

40,100+